Scotiabank initiated coverage of Dyne Therapeutics (DYN) with an Outperform rating and $50 price target The firm thinks the stock pullback on safety concerns over DYNE-251 and management changes create a good entry point for shares ahead of key readouts in late 2025 and first half of 2026 that could enable two submissions for U.S. AA in the first half of 2026. Initial data from both programs support positive results for the registrational studies, Scotiabank adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics price target lowered to $48 from $53 at Piper Sandler
- Buy Rating for Dyne Therapeutics: Promising Accelerated Approval Potential for DYNE-101 and DYNE-251
- Dyne Therapeutics price target lowered to $46 from $55 at H.C. Wainwright
- Dyne Therapeutics Advances Clinical Programs Amid Financial Losses
- Dyne Therapeutics reports Q4 EPS (88c), consensus (91c)